Clinical trials · Tennessee
Cancer clinical trials in Tennessee
We’re tracking 609 recruiting cancer studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Nashville, TennesseeAges 18 years+ - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Nashville, TennesseeAges 18 years+ - NCT06252649RecruitingPhase 3
Study of new drug combo for KRAS G12C colorectal cancer
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
Nashville, TennesseeAges 18 years+ - NCT04831580Recruiting
Robotic vs open hysterectomy for early cervix cancer
This trial compares robotic surgery to open (traditional) surgery for women with early-stage cervix cancer. The goal is to see which approach is safer and works better for cancer control and recovery.
Chattanooga, TennesseeAges 18 years+ - NCT07044336RecruitingPhase 3
Comparing a new drug to chemo for advanced endometrial cancer
This trial tests a new investigational drug called Puxitatug Samrotecan (AZD8205) against standard chemotherapy in people whose endometrial cancer has come back or spread after prior treatment with platinum chemo and an immunotherapy. The goal is to see if the new drug works better.
Knoxville, TennesseeAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Nashville, TennesseeAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Nashville, TennesseeAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Nashville, TennesseeAges 8 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Nashville, TennesseeAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Nashville, TennesseeAges 18 years+ - NCT06712355RecruitingPhase 3
Testing an experimental drug with chemo for newly diagnosed extensive-stage small cell lung cancer
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Germantown, TennesseeAges 18 years+ - NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Memphis, TennesseeAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Nashville, TennesseeAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Nashville, TennesseeAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Germantown, TennesseeAges 18 years+ - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Memphis, TennesseeAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Memphis, TennesseeAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Kingsport, TennesseeAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT03932786Recruiting
Study of health and wellbeing after retinoblastoma treatment
This study looks at long-term health outcomes—how patients are doing physically and in daily life—after treatment for retinoblastoma. It may help doctors understand what support or follow-up care could be most helpful after treatment.
Nashville, TennesseeAges Any age - NCT03945162RecruitingPhase 2
Bladder cancer trial using light therapy in the bladder
This Phase 2 study tests a treatment called photodynamic therapy (PDT) placed directly into the bladder. It may help people whose non–muscle-invasive bladder cancer did not respond to BCG treatment or could not tolerate it.
Nashville, TennesseeAges 18 years+ - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
Nashville, TennesseeAges 18 years+ - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Nashville, TennesseeAges 18 years+
Cancer trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting cancer studies listed above.
- Tennessee Oncology · 5 studies
- Vanderbilt University Medical Center · 5 studies
- SCRI Oncology Partners · 4 studies
- Memphis VA Medical Center · 2 studies
- Research Site · 2 studies
- Sarah Cannon Research Institute · 2 studies
- Urology Associates, P.C. · 2 studies
- West Cancer Center & Research Institute · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Tennessee?
- Yes. We're currently tracking 609 recruiting cancer studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.